Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design - 18/12/20
, Stefan Agewall, MD, PhD b, Dan Atar, MD, PhD b, Tomasz Baron, MD, PhD c, John Beltrame, BMBS, PhD d, Olle Bergström, MD e, David Erlinge, MD, PhD f, Chris P Gale, PhD, FRCP g, Javier López-Pais, MD h, Tomas Jernberg, MD, PhD i, Pelle Johansson j, Annica Ravn-Fisher, MD, PhD k, Harmony R. Reynolds, MD l, Jithendra B. Somaratne, MBChB, FRACP, PhD m, Per Tornvall, MD, PhD n, Bertil Lindahl, MD, PhD cBackground |
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is common and occurs in 6–8% of all patients fulfilling the diagnostic criteria for acute myocardial infarction (AMI). This paper describes the rationale behind the trial ‘Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment (ACEI/ARB) of MINOCA patients’ (MINOCA-BAT) and the need to improve the secondary preventive treatment of MINOCA patients.
Methods |
MINOCA-BAT is a registry-based, randomized, parallel, open-label, multicenter trial with 2:2 factorial design. The primary aim is to determine whether oral beta blockade compared with no oral beta blockade, and ACEI/ARB compared with no ACEI/ARB, reduce the composite endpoint of death of any cause, readmission because of AMI, ischemic stroke or heart failure in patients discharged after MINOCA without clinical signs of heart failure and with left ventricular ejection fraction ≥40%. A total of 3500 patients will be randomized into four groups; e.g. ACEI/ARB and beta blocker, beta blocker only, ACEI/ARB only and neither ACEI/ARB nor beta blocker, and followed for a mean of 4 years.
Summary |
While patients with MINOCA have an increased risk of serious cardiovascular events and death, whether conventional secondary preventive therapies are beneficial has not been assessed in randomized trials. There is a limited basis for guideline recommendations in MINOCA. Furthermore, studies of routine clinical practice suggest that use of secondary prevention therapies in MINOCA varies considerably. Thus results from this trial may influence future treatment strategies and guidelines specific to MINOCA patients.
Le texte complet de cet article est disponible en PDF.Abbreviations : ACEI, AESI, AHA, AMI, ARB, CABG, ESC, CMR, ITT, IVUS, LVEF, MACE, MI-CAD, MINOCA, OCT, PCI, SEPHIA, SWEDEHEART
Plan
| Declarations of interest: none. |
|
| Trial registration EudraCT number: 2018-000889-11. ClinicalTrials.gov identifier: NCT03686696. |
Vol 231
P. 96-104 - janvier 2021 Retour au numéro
Article précédent
- Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol
- Clara K. Chow, Emily R. Atkins, Laurent Billot, John Chalmers, Graham S. Hillis, Peter Hay, Bruce Neal, Mark Nelson, Anushka Patel, Christopher M. Reid, Markus Schlaich, Tim Usherwood, Ruth Webster, Anthony Rodgers
- Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
- C. Michael Gibson, John J.P. Kastelein, Adam T. Phillips, Philip E. Aylward, Megan K. Yee, Michal Tendera, Stephen J. Nicholls, Stuart Pocock, Shaun G. Goodman, John H. Alexander, A. Michael Lincoff, Christoph Bode, Danielle Duffy, Mark Heise, Gail Berman, Sojaita Jenny Mears, Pierluigi Tricoci, Lawrence I. Deckelbaum, P. Gabriel Steg, Paul Ridker, Roxana Mehran
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?